• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mallinckrodt Pharmaceuticals

Mallinckrodt beats Q2 earnings, misses on revenue

August 8, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Shares in Mallinckrodt Pharmaceuticals (NYSE:MNK) fell today after the company beat earnings estimates but missed on revenue with its second quarter results. The U.K.-based company posted profits of $62.8 million, or 72¢ per share, on sales of $824.5 million for the 3 months ended June 30, for bottom-line loss of -68% on sales loss of -5% […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

DOJ subpoenas Mallinckrodt over opioids

August 3, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals (NYSE:MNK) said yesterday that it received a subpoena from the U.S. Dept. of Justice requesting information related to its marketing practices and sales of opioids. The company, which manufactures only generic and non-promoted branded opioids, said that it has worked to prevent misuse and diversion of its products, pointing to efforts like its testimonies […]

Filed Under: Featured, Legal News, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

Mallinckrodt enrolls first infant in registry for inhaled nitric oxide gas

August 1, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that it included the first patient in its Phase IV registry evaluating the use of inhaled Inomax nitric oxide gas for premature neonates compared to term and near-term newborns. Inomax, which has FDA approval, is designed to boost oxygenation and lessen the need for extracorporeal membrane oxygenation in term and near-term […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pediatrics, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

FDA grants regenerative medicine advanced therapy status to Mallinckrodt’s StrataGraft

July 18, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that its StrataGraft regenerative skin tissue won regenerative medicine advanced therapy status from the FDA. The tissue-based therapy is among the first products to be granted the designation. The 21st Century Cures Act, which was passed in 2016, enabled the FDA to give accelerated review approval to products that meet RMAT criteria. […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

Mallinckrodt wins orphan drug status for long-acting muscular dystrophy therapy

July 13, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that the FDA granted orphan drug status to its long-acting cosyntropin acetate formulation, MNK-1411, for the treatment of Duchenne muscular dystrophy. In August last year, the FDA approved the company’s request to fast track its investigational new drug application for the therapy. “We are pleased the FDA has granted orphan drug status to […]

Filed Under: Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

Mallinckrodt responds to probe into pricey injection pain-killer

June 14, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals (NYSE:MNK) issued a response today to Sen. Claire McCaskill (D-Mo.) and her probe into the company’s pricing strategies for its injectable pain-killer, Ofirmev. McCaskill wrote to the company at the end of May, suggesting that that the company’s price increases could have cost hospitals millions and may have pushed healthcare practitioners to use cheaper painkillers, including highly […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

Mallinckrodt launches pivotal trial for StrataGraft regenerative skin graft

June 7, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt (NYSE:MNK) said today that it enrolled the 1st patient in the pivotal Phase III trial of its StrataGraft skin tissue graft. The study is slated to include patients with 3% to 49% total body surface area of severe thermal burns. Researchers intend to evaluate outcomes including the area of StrataGraft treatment site that requires a subsequent […]

Filed Under: Clinical Trials, Featured, Regenerative Medicine Tagged With: Mallinckrodt Pharmaceuticals

Mallinckrodt mulls sale of generics biz

May 31, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals (NYSE:MNK) is reportedly considering a sale of its generic drug unit in an effort to focus its portfolio on high-margin branded drugs, according to a report from Reuters. The divestment comes only months after the company sold its nuclear imaging business to IBA Molecular for $690 million. The sale of its generics business could […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Covidien, Mallinckrodt Pharmaceuticals

Mallinckrodt faces probe over price hikes for injectable pain-killer

May 30, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Sen. Claire McCaskill (D-Mo.) penned a letter to Mallinckrodt Pharmaceuticals (NYSE:MNK) last week, probing for details about the company’s pricing strategies for its injectable pain-killer, Ofirmev. Mallinckrodt acquired Ofirmev in 2014, when it bought Cadence Pharmaceuticals in a $1.4 billion deal. In May of that year, Mallinckrodt hiked the pain-killer’s list price from $14.75 per vial to […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Mallinckrodt Pharmaceuticals

Amid drug-pricing criticism, industry trade group ousts members

May 12, 2017 By Sarah Faulkner

Prescription drugs

The pharmaceutical industry’s trade group ousted 22 companies earlier this week after it revised membership rules. The move comes as lawmakers in Washington have pressed the pharma industry about U.S. drug prices. The updated membership rules for the Pharmaceutical Research and Manufacturers of America (PhRMA) group mandates that members spend at least $200 million each year […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Aerie Pharmaceuticals, amagpharmaceuticals, GlaxoSmithKline plc, jazzpharmaceuticals, johnsonandjohnson, Mallinckrodt Pharmaceuticals, Marathon Pharmaceuticals, Pfizer Inc., The Medicines Co.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS